What is the dead-space loss per draw with a 31G needle at 4 mg/mL?

Details up front: a 31G needle · 4 mg/mL.

This should be a straightforward calculation and I keep getting two different answers.

The numbers are arbitrary; the method is what I am after.

Can someone walk through the arithmetic step by step?

Dead space is the volume trapped in the syringe hub and needle after the plunger bottoms out, and it is the reason your 10 mg vial yields only 9.5 mg of usable draws.

Be sceptical of anything advertised as low dead space that retains a conventional plunger tip: if you can look into the fitting with the plunger fully forward and see an open conical void, that void is your dead space.

The luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.

Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.

The caveat is that dead space is a yield loss and not a dose-accuracy loss, so the person feeling this loss most is the person with the most total draws.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

edited 16 Apr 2026 by Dr_Ravi_Selvarajah — tightened the wording; no substantive change

The distinction that resolves most of these questions is understanding that dead space is a fixed volume — typically 3 to 5 µL in a fixed-needle syringe and 35 to 100 µL in a luer-lock — and its cost scales with how small your draws are.

Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.

Concretely, at 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.

The limitation is that even with perfect technique, some loss is irreducible unless you switch to a low-dead-space syringe.

If cost matters, this is the first thing to change, not the last.

The underlying point is that changing syringe architecture changes everything, while changing needle gauge changes almost nothing.

Corollary that follows immediately: changing needle gauge or length barely changes your losses.

Delivered peptide = 10 x 0.5 mg = 5.0 mg. Lost to dead space = 10 x 84 µL = 840 µL x 0.005 = 4.2 mg. Yield = 50 per cent.

The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.

The switch nearly doubles your vial, which is better than most other optimisations combined.

At 100 µL draws the dead-space penalty with a luer-lock is 84 per cent per draw — the cost is genuinely catastrophic.

Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.

Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

Specifically, the switch to a low-dead-space syringe nearly doubles your usable vial, which is better than switching suppliers if you are looking for cost savings.

The complete rule: fix the syringe architecture first, and then the reconstitution volume becomes a free choice you can make on stability grounds rather than on economics.

One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.

If cost matters, this is the first thing to change, not the last.